Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study

Scherwath, Angela; Schirmer, Lena; Kruse, Margitta; Ernst, Gundula; Eder, Matthias; Dinkel, Andreas; Kunze, Sabine; Balck, Friedrich; Bornhäuser, Martin; Ehninger, Gerhard; Dolan, Karin; Gramatzki, Martin; Kolb, Hans‐Jochem; Heußner, Pia; Wilhelm, Hans; Beelen, Dietrich; Schulz-Kindermann, Frank; Zander, Axel R.; Koch, Uwe; Mehnert, Anja

doi:10.1002/pon.3159

Cited by 81 publications

(73 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients completed the set of questionnaires at home and brought them to the scheduled oncology follow-up appointment at the Department of Stem Cell Transplantation, where also the neuropsychological assessment was performed (data published elsewhere). 16 …”

Section: Methodsmentioning

confidence: 99%

“…16 Patients were recruited from six German university medical centers in Hamburg, Hannover, Dresden, Kiel, Essen and Munich and were assessed before conditioning/at admission (pre-HSCT), 100 ± 20 days after allogeneic HSCT (100 days after HSCT) and 12 ± 1 months after HSCT (1 year following HSCT). Data were collected over a 3-year period from June 2005 to July 2008.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

Sarkar

Scherwath

Schirmer

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

We examined the course and the prevalence of a high fear of cancer recurrence (FCR) in patients undergoing allogeneic PBSC transplantation (hematopoietic SCT (HSCT)) before HSCT (N = 239), 100 days after (n = 150, and 12 months after allogeneic HSCT (n = 102). The Fear of Progression Questionnaire-Short Form (FoP-Q-SF), the EORTC Quality of Life Questionnaire, and the Hospital Anxiety and Depression Scale were used. Pre-HSCT 36% of patients, 100 days after HSCT 24% of patients, and 1 year after HSCT 23% of patients fulfilled the criteria for high FCR (FoP-Q-SF cutoff = 34). Being married (b = 2.76, P = 0.026), female gender (b = 4.45, Po 0.001) and depression (b = 4.44, P o 0.001) were significantly associated with FCR at baseline. One hundred days after HSCT, depression significantly predicted FCR (b = 6.46, Po 0.001). One year following HSCT, female gender (b = 6.61, P = 0.008) and higher depression were (b = 4.88, P = 0.004) significant predictors for FCR. Over the three assessment points, patients with high FCR had a significantly lower quality of life compared to patients with low FCR in physical functioning (P = 0.019), role functioning (P = 0.003), emotional functioning (P o 0.001), cognitive functioning (P = 0.003), social functioning (P o 0.001) and global quality of life (P o 0.001). Our data provide evidence that FCR is a prevalent problem in patients with hematological malignancies and has a significant adverse impact on health-related quality of life.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

Sarkar

Scherwath

Schirmer

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Newer therapeutic modalities are also associated with adverse cognitive outcomes. Allogeneic hematopoietic stem cell transplantation is associated with risk of temporary cognitive disability [49]. Patients before allogeneic hematopoietic stem cell transplantation may show slow word fluency and impairment on cognitive domains, while after transplantation they may exhibit fine motor dysfunction and delayed verbal answering [49].…”

Section: Consequences Of the Hypothesis And Discussionmentioning

confidence: 99%

Perforin- and granulysin-mediated cytotoxicity and interleukin 15 play roles in neurocognitive impairment in patients with acute lymphoblastic leukaemia

Petranović¹,

Pilčić²,

Valković³

et al. 2014

Medical Hypotheses

View full text Add to dashboard Cite

“…Also Sherwart et al, reported cognitive dysfunction pre-and post HSCT in 102 patients [11]. Before and after transplantation 50% performed below tests norms.…”

Section: Cognitive Impairment Associated With Hematopoietic Cell Tranmentioning

confidence: 99%

Successful treatment of stress-induced cognitive impairment with haloperidol; evaluation also warranted in hematopoietic stem cell transplantation

Hoef¹

2015

Hematol Leuk

View full text Add to dashboard Cite

Cognitive impairment in patients with hematologic malignancies has been reported since over two decades and has been observed in the course of treatment prior to and after hematopoietic stem cell transplantation. Most reports attribute the dysfunction to the effect of treatment on the nervous system and focus on diagnosis and a battery of cognitive function tests. Whether cognitive impairment results from the effect of the treatment or is stress related has not been examined. Effective therapy is not known. Spontaneous improvement by time has been reported. Herein literature is reviewed, a case of stress induced cognitive impairment presented, successful treatment for the dysfunction described and the physiological mechanism explained.

show abstract

Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study

Abstract: Below average cognitive performance is common in this patient group. In addition, a subgroup shows reliable cognitive decline after allogeneic HSCT. Healthcare professionals should be aware of these treatment-related cognitive side effects.

Cited by 81 publications

References 33 publications

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

Perforin- and granulysin-mediated cytotoxicity and interleukin 15 play roles in neurocognitive impairment in patients with acute lymphoblastic leukaemia

Successful treatment of stress-induced cognitive impairment with haloperidol; evaluation also warranted in hematopoietic stem cell transplantation

Contact Info

Product

Resources

About